Lundbeck made an undisclosed payment to Ossianix on Thursday following experiments with mice that successfully transferred drugs across the blood-brain barrier — a protective sheath surrounding the brain’s blood supply. While the barrier prevents germs and toxins from entering the brain, it also blocks helpful medicines.
Ossianix may have found a solution to this problem from an unlikely source — sharks.
The biotech discovered a method to attach therapeutic proteins to antibodies derived from sharks, which allows the treatments to easily travel across the barrier and into the brain, according to the report.
While the technology is still years away from reaching the market, Lundbeck’s research head Kim Andersen said it holds “significant potential” to deliver antibody-based medicines and into the brain, reports Reuters.
More articles on supply chain:
17 pharma companies’ stock prices dropped after Trump’s ‘getting away with murder’ speech
Trump administration proposes 20% tax on Mexican goods: 5 things to know
Prologis CEO: Warehouse shortage coming to an end
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
